Connor, Clark & Lunn Investment Management Ltd. Alpine Immune Sciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Alpine Immune Sciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 13,357 shares of ALPN stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,357
Previous 11,909
12.16%
Holding current value
$0
Previous $226,000
134.07%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ALPN
# of Institutions
185Shares Held
62MCall Options Held
158KPut Options Held
199K-
Decheng Capital LLC Menlo Park, CA8.32MShares$044.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.78MShares$02.76% of portfolio
-
Black Rock Inc. New York, NY3.58MShares$00.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.13MShares$06.52% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.08MShares$00.01% of portfolio
About ALPINE IMMUNE SCIENCES, INC.
- Ticker ALPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,006,700
- Description
- Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...